Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
Big news of the day is that Biogen and Eisai are scrapping the amyloid beta antibody aducanumab program for Alzheimer's. That caused a $15 billion drop in Biogen market cap. Great opportunity here for apabetalone to impress in the BETonMACE cognition sub-study.
